Known cancer admission
When Is Gyn Onc Discussion Reasonable for Known Gyn Cancer Admission?
A concise clinician-facing triage reference for known gyn cancer presentations, complications, and admission questions.
Quick answer
Known Gyn Cancer Admission
- Known gyn cancer does not mean every admission belongs to Gyn Onc.
- Early Gyn Onc discussion is reasonable when active treatment, recent Gyn Onc surgery, recurrence/progression, malignant obstruction, bleeding, or oncologic disposition is part of the decision.
- Use medicine, surgery, benign gyn, oncology, or another service when the acute problem is not cancer-directed.
Gyn Onc discussion is reasonable when
Cancer-Directed Decisions
- Active treatment or Gyn Onc surgery within 30 days.
- Concern for recurrence, progression, malignant obstruction, ascites, bleeding from known tumor, or treatment toxicity.
- The decision affects staging, therapy, surgery, continuity, or oncologic disposition.
Another service is usually the better first call when
Better First Step
- The acute issue is primarily medical and cancer history is background context.
- General oncology, medicine, surgery, or another specialty owns the presenting problem.
- Gyn Onc input would not change today’s disposition or treatment plan.
Common pitfall
Cancer History Is Not Always the Admitting Service
Lead with the acute problem. Then ask whether Gyn Onc changes today’s disposition, cancer-directed plan, or continuity.
FAQ
Clinician Questions
Does known gyn cancer require Gyn Onc admission?
No. The admitting service should match the acute problem unless cancer-directed decisions or continuity make Gyn Onc central.
When is medicine the better admitting service?
Medicine is often better when the problem is primarily medical and Gyn Onc input would not change the immediate plan.
What complications make Gyn Onc discussion more useful?
Recent Gyn Onc surgery, active treatment, recurrence/progression concern, malignant obstruction, tumor bleeding, or oncologic disposition questions should make early discussion reasonable.
References
- [1] ASCO resource-stratified ovarian masses and epithelial ovarian cancer guidance.
- [2] NCCN Guidelines for Patients for ovarian, fallopian tube, and primary peritoneal cancers.
Educational tool only. SIC provides clinician-facing educational consult-triage references. SIC does not diagnose, treat, prevent, cure, or mitigate disease and is not a substitute for clinical judgment, local guidelines, institutional referral pathways, or recommendations from your gynecologic oncology department. See disclaimer and how SIC works.